The Roles And Signaling Pathways Of Phosphatidylethanolamine-Binding Protein 4 In Tumors

References

• Aribike O, Okafor I, Roberts A, Odugbemi T. Are Nigerian women pro-active about noncommunicable disease prevention? A quantitative survey. Ann Glob Health. 2019;85(1).
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. doi:10.3322/caac.2138728055103
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Garcia R, Grindlay J, Rath O, Fee F, Kolch W. Regulation of human myoblast differentiation by PEBP4. EMBO Rep. 2009;10(3):278–284. doi:10.1038/embor.2009.419197339
   PubMed Web of Science ®Google Scholar
• Al-Mulla F, Bitar MS, Taqi Z, Yeung KC. RKIP: much more than Raf kinase inhibitory protein. J Cell Physiol. 2013;228(8):1688–1702. doi:10.1002/jcp.2433523359513
   PubMed Web of Science ®Google Scholar
• Fagerberg L, Hallström BM, Oksvold P, et al. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol Cell Proteomics. 2014;13(2):397–406. doi:10.1074/mcp.M113.03560024309898
   PubMed Web of Science ®Google Scholar
• Yeung K, Janosch P, McFerran B, et al. Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the raf kinase inhibitor protein. Mol Cell Biol. 2000;20(9):3079–3085. doi:10.1128/mcb.20.9.3079-3085.200010757792
   PubMed Web of Science ®Google Scholar
• He H, Liu D, Lin H, et al. Phosphatidylethanolamine binding protein 4 (PEBP4) is a secreted protein and has multiple functions. Biochim Biophys Acta. 2016;1863(7 Pt A):1682–1689. doi:10.1016/j.bbamcr.2016.03.02227033522
   PubMed Web of Science ®Google Scholar
• Wu Z, Liu B, Zheng X, Hou H, Li Y. Role of the PEBP4 protein in the development and metastasis of gastric cancer. Oncotarget. 2017;8(11):18177–18184. doi:10.18632/oncotarget.1525528193908
   PubMedGoogle Scholar
• Wang X, Li N, Liu B, et al. A novel human phosphatidylethanolamine-binding protein resists tumor necrosis factor alpha-induced apoptosis by inhibiting mitogen-activated protein kinase pathway activation and phosphatidylethanolamine externalization. J Biol Chem. 2004;279(44):45855–45864. doi:10.1074/jbc.M40514720015302887
   PubMed Web of Science ®Google Scholar
• Wang K, Jiang Y, Zheng W, et al. Silencing of human phosphatidylethanolamine-binding protein 4 enhances rituximab-induced death and chemosensitization in B-cell lymphoma. PLoS One. 2013;8(2):e56829. doi:10.1371/journal.pone.005682923451095
   PubMed Web of Science ®Google Scholar
• Liu H, Qiu J, Li N, Chen T, Cao X. Human phosphatidylethanolamine-binding protein 4 promotes transactivation of estrogen receptor alpha (ERalpha) in human cancer cells by inhibiting proteasome-dependent ERalpha degradation via association with Src. J Biol Chem. 2010;285(29):21934–21942. doi:10.1074/jbc.M110.10987620460377
   PubMed Web of Science ®Google Scholar
• Yang Y, Yang HH, Hu Y, et al. Immunocompetent mouse allograft models for development of therapies to target breast cancer metastasis. Oncotarget. 2017;8(19):30621–30643. doi:10.18632/oncotarget.1569528430642
   PubMedGoogle Scholar
• Wang X, Li N, Li H, et al. Silencing of human phosphatidylethanolamine-binding protein 4 sensitizes breast cancer cells to tumor necrosis factor-alpha-induced apoptosis and cell growth arrest. Clin Cancer Res. 2005;11(20):7545–7553. doi:10.1158/1078-0432.CCR-05-087916243830
   PubMed Web of Science ®Google Scholar
• Wang S-C, Zhou F, Zhou Z-Y, Hu Z, Chang L, Ma M-D. Knockdown of PEBP4 suppresses proliferation, migration and invasion of human breast cancer cells. Biomed Pharmacother. 2017;90:659–664. doi:10.1016/j.biopha.2017.03.09828415045
   PubMed Web of Science ®Google Scholar
• Jian W, Bai Y, Li X, Kang J, Lei Y, Xue Y. Phosphatidylethanolamine-binding protein 4 promotes the epithelial-to-mesenchymal transition in non-small cell lung cancer cells by activating the sonic hedgehog signaling pathway. J Cell Biochem. 2018;120:5386–5395.30367510
   PubMedGoogle Scholar
• Yu G, Shen Z, Chen G, Teng X, Hu Y, Huang B. PEBP4 enhanced HCC827 cell proliferation and invasion ability and inhibited apoptosis. Tumour Biol. 2013;34(1):91–98. doi:10.1007/s13277-012-0514-022983920
   PubMedGoogle Scholar
• Lelli D, Pedone C, Majeed M, Sahebkar A. Curcumin and lung cancer: the role of microRNAs. Curr Pharm Des. 2017;23(23):3440–3444. doi:10.2174/138161282366617010914481828067164
   PubMed Web of Science ®Google Scholar
• Del VV, Denti MA. microRNA and lung cancer. Adv Exp Med Biol. 2015;889:153–177. doi:10.1007/978-3-319-23730-5_926659001
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yang Q, Wang S. MicroRNAs: a new key in lung cancer. Cancer Chemother Pharmacol. 2014;74(6):1105–1111. doi:10.1007/s00280-014-2559-925135624
   PubMed Web of Science ®Google Scholar
• Zhao Z, Zhang L, Yao Q, Tao Z. miR-15b regulates cisplatin resistance and metastasis by targeting PEBP4 in human lung adenocarcinoma cells. Cancer Gene Ther. 2015;22(3):108–114. doi:10.1038/cgt.2014.7325721211
   PubMed Web of Science ®Google Scholar
• Yu G, Zhong N, Chen G, Huang B, Wu S. Downregulation of PEBP4, a target of miR-34a, sensitizes drug-resistant lung cancer cells. Tumour Biol. 2014;35(10):10341–10349. doi:10.1007/s13277-014-2284-325038915
   PubMedGoogle Scholar
• Ma Z, Zhu J, Han G, et al. PEBP4 is upregulated in gastric cancer and promotes the growth and migration of cancer cells. Int J Clin Exp Med. 2016;9(7):12687–12695.
   Web of Science ®Google Scholar
• Liu H, Kong Q, Li B, He Y, Li P, Jia B. Expression of PEBP4 protein correlates with the invasion and metastasis of colorectal cancer. Tumour Biol. 2012;33(1):267–273. doi:10.1007/s13277-011-0279-x22125029
   PubMedGoogle Scholar
• Qiu J, Tao Y, Yang G, Xu K, Lin AL, Li L. Effect of a chemical inhibitor of human phosphatidylethanolamine-binding protein 4 on radiosensitivity of rectal cancer cells. World J Surg Oncol. 2016;14(1):221. doi:10.1186/s12957-016-0977-327553494
   PubMedGoogle Scholar
• Qiu J, Yang G, Shen Z, Xie Y, Wang L. hPEBP4 as a predictive marker for the pathological response of rectal cancer to preoperative radiotherapy. Int J Colorectal Dis. 2013;28(2):241–246. doi:10.1007/s00384-012-1534-322801881
   PubMed Web of Science ®Google Scholar
• Olow A, Mueller S, Yang X, et al. BRAF status in personalizing treatment approaches for pediatric gliomas. Clin Cancer Res. 2016;22(21):5312–5321. doi:10.1158/1078-0432.CCR-15-110127217440
   PubMed Web of Science ®Google Scholar
• Berghoff AS, Kiesel B, Widhalm G, et al. Correlation of immune phenotype with IDH mutation in diffuse glioma. Neuro Oncol. 2017;19(11):1460–1468. doi:10.1093/neuonc/nox05428531337
   PubMed Web of Science ®Google Scholar
• Huang R-Q, Shi D-L, Huang W, Chen F, Lu Y-C. Increased expression of phosphatidylethanolamine-binding protein 4 (PEBP4) strongly associates with human gliomas grade. J Neurooncol. 2016;127(2):235–242. doi:10.1007/s11060-015-2040-626725095
   PubMed Web of Science ®Google Scholar
• Huang RQ, Wang SQ, Zhu QB, et al. Knockdown of PEBP4 inhibits human glioma cell growth and invasive potential via ERK1/2 signaling pathway. Mol Carcinog. 2019;58(1):135–143. doi:10.1002/mc.2291530255656
   PubMed Web of Science ®Google Scholar
• Batra R, Kaur H, Jindal S. Extranodal large B-cell type aggressive non-Hodgkin’s lymphoma. Indian J Dent. 2014;5(4):225–228. doi:10.4103/0975-962X.14474225565759
   PubMedGoogle Scholar
• Jacquemin G, Granci V, Gallouet AS, et al. Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin’s lymphoma B cells. Haematologica. 2012;97(1):38–46. doi:10.3324/haematol.2011.04646621933852
   PubMed Web of Science ®Google Scholar
• Stolz C, Schuler M. Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention. Leuk Lymphoma. 2009;50(6):873–885. doi:10.1080/1042819090287847119373595
   PubMed Web of Science ®Google Scholar
• Wang Q, Chen X, Hay N. Akt as a target for cancer therapy: more is not always better (lessons from studies in mice). Br J Cancer. 2017;117(2):159–163. doi:10.1038/bjc.2017.15328557977
   PubMed Web of Science ®Google Scholar
• Brown JS, Banerji U. Maximising the potential of AKT inhibitors as anti-cancer treatments. Pharmacol Ther. 2017;172:101–115. doi:10.1016/j.pharmthera.2016.12.00127919797
   PubMed Web of Science ®Google Scholar
• Lien EC, Dibble CC, Toker A. PI3K signaling in cancer: beyond AKT. Curr Opin Cell Biol. 2017;45:62–71. doi:10.1016/j.ceb.2017.02.00728343126
   PubMed Web of Science ®Google Scholar
• Li W, Dong Y, Zhang B, Kang Y, Yang X, Wang H. PEBP4 silencing inhibits hypoxia-induced epithelial-to-mesenchymal transition in prostate cancer cells. Biomed Pharmacother. 2016;81:1–6. doi:10.1016/j.biopha.2016.03.03027261570
   PubMed Web of Science ®Google Scholar
• Yu G, Huang B, Chen G, Mi Y. Phosphatidylethanolamine-binding protein 4 promotes lung cancer cells proliferation and invasion via PI3K/Akt/mTOR axis. J Thorac Dis. 2015;7(10):1806–1816. doi:10.3978/j.issn.2072-1439.2015.10.1726623104
   PubMed Web of Science ®Google Scholar
• Zhang D, Dai Y, Cai Y, et al. PEBP4 promoted the growth and migration of cancer cells in pancreatic ductal adenocarcinoma. Tumour Biol. 2016;37(2):1699–1705. doi:10.1007/s13277-015-3906-026311050
   PubMedGoogle Scholar
• Zhao Y, Hu X, Liu Y, et al. ROS signaling under metabolic stress: cross-talk between AMPK and AKT pathway. Mol Cancer. 2017;16(1):79. doi:10.1186/s12943-017-0648-128407774
   PubMedGoogle Scholar
• Burkhard K, Smith S, Deshmukh R, MacKerell AD, Shapiro P. Development of extracellular signal-regulated kinase inhibitors. Curr Top Med Chem. 2009;9(8):678–689. doi:10.2174/15680260978904441619689374
   PubMed Web of Science ®Google Scholar
• Tanimura S, Takeda K. ERK signalling as a regulator of cell motility. J Biochem. 2017;162(3):145–154. doi:10.1093/jb/mvx04828903547
   PubMed Web of Science ®Google Scholar
• Chen RH, Sarnecki C, Blenis J. Nuclear localization and regulation of erk- and rsk-encoded protein kinases. Mol Cell Biol. 1992;12(3):915–927. doi:10.1128/mcb.12.3.9151545823
   PubMed Web of Science ®Google Scholar
• Caunt CJ, Sale MJ, Smith PD, Cook SJ. MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nat Rev Cancer. 2015;15(10):577–592. doi:10.1038/nrc400026399658
   PubMed Web of Science ®Google Scholar
• Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol. 2008;9(7):517–531. doi:10.1038/nrm243818568040
   PubMed Web of Science ®Google Scholar
• Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol. 2004;5(11):875–885. doi:10.1038/nrm149815520807
   PubMed Web of Science ®Google Scholar
• Li H, Wang X, Li N, Qiu J, Zhang Y, Cao X. hPEBP4 resists TRAIL-induced apoptosis of human prostate cancer cells by activating Akt and deactivating ERK1/2 pathways. J Biol Chem. 2007;282(7):4943–4950. doi:10.1074/jbc.M60949420017178731
   PubMed Web of Science ®Google Scholar